首页> 外文期刊>Acta Virologica: International Journal >Recombinant beta interferon could clear the low-dose infected porcine reproductive and respiratory syndrome virus (PRRSV) in MARC-145 cells
【24h】

Recombinant beta interferon could clear the low-dose infected porcine reproductive and respiratory syndrome virus (PRRSV) in MARC-145 cells

机译:重组β干扰素可清除MARC-145细胞中低剂量感染的猪繁殖与呼吸综合征病毒(PRRSV)

获取原文
获取原文并翻译 | 示例
           

摘要

Porcine reproductive and respiratory syndrome virus (PRRSV) causes one of the most economically devastating and pandemic porcine diseases. Previous study has shown that MARC-145 cells pretreated with recombinant IFN-beta (rIFN-beta) couldn't develop cytopathic effect (CPE) of PRRSV. However, up to date, it is not clear whether MARC-145 cells post-treated with rIFN-beta could develop CPE of PRRSV. The present work showed that the MARC-145 cells didn't develop the CPE at 120 hr post-infection (p.i.) with low-dose of PRRSV when the cells were pre-treated with rIFN-beta (Group 1), post-treated with rIFN-beta at 4 hr p.i. (Group 2), or post-treated with rIFN-beta at 8 hr p.i. (Group 3), while the MARC-145 cells could develop CPE when the cells were infected with high-dose PRRSV and then treated with rIFN-beta at 24 hr p.i.. Furthermore, the indirect immunofluorescence assay confirmed that there were a few N protein-positive cells in the high-dose infected cells in Group 1, Group 2 and Group 3, while there were no N protein-positive cells in the low-dose infected. cells in all rIFN-beta treatment groups. In addition, the numbers of N protein-positive cells in high-dose infected cells (MOI = 10) in Group 1 were lower than that in Group 2 and Group 3. The results above demonstrated that both pre-treatment with rIFN-beta and an earlier post-treatment with rIFN-beta could inhibit the PRRSV replication and could clear the low-dose infected PRRSV, which indicated that the rIFN-beta had efficient antiviral activities when the cells have been infected with PRRSV.
机译:猪繁殖与呼吸综合症病毒(PRRSV)引起最具经济破坏力的大流行性猪疾病之一。先前的研究表明,用重组IFN-β(rIFN-beta)预处理的MARC-145细胞不能发展PRRSV的细胞病变效应(CPE)。然而,到目前为止,尚不清楚用rIFN-β后处理的MARC-145细胞是否会发展PRRSV的CPE。目前的工作表明,当用rIFN-beta预处理后,低剂量的PRRSV感染后(pi),MARC-145细胞未发育成CPE(第1组),后处理于pi 4小时使用rIFN-beta (第2组),或在r.i. 8小时后以rIFN-beta进行后处理。 (第3组),当高剂量PRRSV感染MARC-145细胞并在pi 24小时用rIFN-beta处理时,MARC-145细胞可能会发展为CPE。此外,间接免疫荧光试验证实,其中有少量N蛋白1组,2组和3组高剂量感染细胞中存在N阳性细胞,而低剂量感染细胞中没有N蛋白阳性细胞。所有rIFN-beta治疗组中的细胞。此外,第1组高剂量感染细胞(MOI = 10)中N蛋白阳性细胞的数量低于第2组和第3组。以上结果表明,rIFN-β预处理和较早地用rIFN-β进行后处理可以抑制PRRSV复制并清除低剂量感染的PRRSV,这表明当细胞被PRRSV感染后,rIFN-β具有有效的抗病毒活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号